AirSculpt reported third-quarter revenue of $31.9 million, down 8.7%, and cut full-year 2026 revenue guidance to $144 million to $146 million and adjusted EBITDA guidance to $9 million to $10 million after weaker marketing productivity and center execution.
AIRS · Airsculpt Technologies, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
AirSculpt Technologies, Inc. reported that revenue decreased $4.1 million, or 3.5%, for the nine months ended September 30, 2026 compared to the same period in 2025, driven primarily by a 2.1% decrease in same center volume.
AirSculpt Technologies entered a $39.0 million senior secured term loan and up to $5.0 million revolving facility on November 5, 2026, repaying its existing credit agreement in full; the facilities mature November 5, 2031.
AirSculpt Technologies reported third-quarter revenue of $31.9 million, down 8.7%, and cut 2026 revenue guidance to approximately $144 million to $146 million and Adjusted EBITDA guidance to approximately $9 million to $10 million. It also refinanced its term loan, extending maturity to 2031.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 10, 2026TL;DR. AirSculpt reported Q2 revenue down 3% to $42.9M with adjusted EBITDA of $4.9M (vs. $5.8M), cut its full-year adjusted EBITDA outlook to $12–$14M, and reaffirmed revenue at the low end of $151–$157M; same-center cases grew 1% and the company expanded its AlloClae partnership and new procedures, while customer acquisition cost rose to ~$3,500 from $2,900.
- + Same-center case volume grew 1.0% in Q2 and 1.1% YTD versus prior year.
- + Entered an exclusive AlloClae partnership and is piloting the new procedure later this quarter.
- + Skin tightening and skin removal procedures carry similar ~60% gross margin profile to core fat removal business and lift average ticket.
- − Q2 revenue declined 3% to $42.9M and YTD revenue fell 1.3% to $82.3M.
- − Adjusted EBITDA fell to $4.9M in Q2 from $5.8M and YTD to $8.2M from $9.6M, with margins compressing to 11.5%/10.0% from 13.3%/11.5%.
- − Full-year 2026 adjusted EBITDA outlook reduced to approximately $12–$14M.
- − Full-year 2026 revenue reaffirmed only at the lower end of the $151–$157M guidance range.
- − Q2 customer acquisition cost rose to ~$3,500 from ~$2,900 a year ago, lifting marketing to ~20% of revenue from ~18%.
- − Q2 net loss widened to $1.1M from $0.6M and YTD net loss to $3.5M from $3.4M.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $8.6M | First Nine Months 2026 | — |
|
|
|||
| Adjusted EBITDA margin non-GAAP | 7.6% | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Adjusted net (loss)/income non-GAAP | -$6.32M | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Adjusted net loss per share of common stock - Basic non-GAAP | -$0.09 | Nine Months Ended September 30, 2026 | — |
| Adjusted net loss per share of common stock - Diluted non-GAAP | -$0.09 | Nine Months Ended September 30, 2026 | — |
| Case growth | -2.1% | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Case volume | 8,941 | First Nine Months 2026 | — |
|
|
|||
| Number of facilities | 31 | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Number of total procedure rooms | 65 | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Revenue per case | $12,776 | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Revenue per case growth | 2.3% | Three Months Ended September 30, 2026 | — |
|
|
|||
| Same-center Case growth | -2.1% | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Same-center Cases | 8,941 | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Same-center Number of facilities | 31 | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Same-center Number of total procedure rooms | 65 | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Same-center Revenue per case | $12,776 | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Same-center Revenue per case growth | 2.3% | Three Months Ended September 30, 2026 | — |
|
|
|||
| Adjusted Net Income per share - Basic non-GAAP | $0.01 | Three Months Ended June 30, 2026 filing | — |
| Adjusted Net Income per share - Diluted non-GAAP | $0.01 | Three Months Ended June 30, 2026 filing | — |
| Customer acquisition costs | $3,467 | the three months ended June 30, 2026 filing | — |
| Same center case volume growth | 1% | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AIRS
this stock
Airsculpt Technologies, Inc.
|
$61.88M | -57.7% | -15.8% | — | 4.4% |
|
HCA
HCA Healthcare, Inc.
|
$104.25B | +6.9% | +7.1% | 16.6 | 2.3% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$33.34B | +3.3% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$22.76B | +43.9% | +0.9% | 8.3 | 2.2% |
|
EHC
Encompass Health Corp
|
$13.83B | +32.8% | +10.5% | 22.0 | 3.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 6, 2026
- This year
- 20
AirSculpt Technologies entered a $39.0 million senior secured term loan and up to $5.0 million revolving facility on November 5, 2026, repaying its existing credit agreement in full; the facilities mature November 5, 2031.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AIRS | +56.8% | -34.4% | -84.8% | -51.6% | -57.7% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +54.2% | -33.2% | -85.3% | -51.4% | -68.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.